Teresa A. Foster

MEDI 351-Toward "best-in-class" Hsp90 inhibitors: Design, biosynthesis and preclinical profiles

Thomas Greiner, Nigel Coates, Christine J. Martin, 2007 .

Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate

Christine J. Martin, Teresa A. Foster, M. Gregory, 2011, Proceedings of the National Academy of Sciences.

Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family

Teresa A. Foster, M. Gregory, B. Wilkinson, 2011, Antimicrobial Agents and Chemotherapy.

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

Teresa A. Foster, M. Gregory, B. Wilkinson, 2012 .

Novel FK506 and FK520 analogues via mutasynthesis: mutasynthon scope and product characteristics

Christine J. Martin, Teresa A. Foster, M. Gregory, 2013 .

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.

Mohammad Nur-E-Alam, Christine J. Martin, Sabine Gaisser, 2008, Journal of medicinal chemistry.

Recombinant strains for the enhanced production of bioengineered rapalogs.

Christine J. Martin, Teresa A. Foster, M. Gregory, 2013, Metabolic engineering.